UB Paderborn / Katalog / Suche / in CDI

Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer

Annals of oncology, 2014-10, Vol.25 (10), p.1959-1965

2014

Volltextzugriff (PDF)

Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer

Annals of oncology, 2022-08, Vol.33 (8), p.769-785

2022

Volltextzugriff (PDF)

Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4

Cell death and differentiation, 2006-06, Vol.13 (6), p.927-934

2006

Volltextzugriff (PDF)

The AURORA initiative for metastatic breast cancer

British journal of cancer, 2014-11, Vol.111 (10), p.1881-1887

2014

Volltextzugriff (PDF)

Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers

Annals of oncology, 2016-10, Vol.27 (10), p.1860-1866

2016

Volltextzugriff (PDF)

Corrigendum to “Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer”: [Annals of Oncology 33 (2022) 769–785]

Annals of oncology, 2023-03, Vol.34 (3), p.326-326

2023

Volltextzugriff (PDF)

SYNERGY: Phase I and randomized phase II trial to investigate the addition of the anti-CD73 antibody oleclumab to durvalumab, paclitaxel and carboplatin for previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)

Annals of oncology, 2019-05, Vol.30, p.iii62-iii62

2019

Volltextzugriff (PDF)

Neoadjuvant biomarker research study of palbociclib combined with endocrine therapy in estrogen receptor positive/HER2 negative breast cancer: The phase II NeoRHEA trial

Annals of oncology, 2018-10, Vol.29, p.viii57-viii57

2018

Volltextzugriff (PDF)

Perianal Mucinous Adenocarcinoma Arising from a Chronic Fistula-In-Ano

Acta chirurgica belgica, 2014-01, Vol.114 (6), p.410-413

2014

Volltextzugriff (PDF)

1811 Expression levels of ERBB2, ESR1, immune and proliferation signatures measured by RNASeq predict response to anti-HER2 treatment in the neoALTTO trial

European journal of cancer (1990), 2015-09, Vol.51, p.S269-S269

2015

Volltextzugriff (PDF)

2251P The genomic landscape of radiotherapy-induced breast angiosarcoma: An alleanza contro il cancro (ACC) initiative for an unmet need in rare tumors

Annals of oncology, 2023-10, Vol.34, p.S1159-S1159

2023

Volltextzugriff (PDF)

Mdm4 and Mdm2 Cooperate to Inhibit p53 Activity in Proliferating and Quiescent Cells in vivo

Proceedings of the National Academy of Sciences - PNAS, 2006-02, Vol.103 (9), p.3232-3237

2006

Volltextzugriff (PDF)

139MO Identification of biologically-driven HER2-positive breast cancer subgroups associated with prognosis after adjuvant trastuzumab in the ALTTO trial

Annals of oncology, 2022-09, Vol.33, p.S602-S603

2022

Volltextzugriff (PDF)

67P Digital analysis of distant and cancer-associated adipocytes in breast cancer

Annals of oncology, 2020-05, Vol.31, p.S37-S38

2020

Volltextzugriff (PDF)

ALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early stage triple negative breast cancer

Annals of oncology, 2019-10, Vol.30, p.v97

2019

Volltextzugriff (PDF)

289TiP - ALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early stage triple negative breast cancer

Annals of oncology, 2019-10, Vol.30, p.v97-v97

2019

Volltextzugriff (PDF)

91P The lack of documentation of patient’s body mass index (BMI) in recent clinical trials

ESMO open, 2023-05, Vol.8 (1), p.101314, Article 101314

2023

Volltextzugriff (PDF)

Abstract P1-05-02: Genomic, transcriptomic and immune features of breast cancer according to the patient's body mass index at diagnosis

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P1-P1-05-02

2017

Volltextzugriff (PDF)

Abstract P2-05-04: Deregulation of A-to-I RNA editing is associated with poor prognosis in HER2+ breast cancers in the neoALTTO trial

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P2-P2-05-04

2018

Volltextzugriff (PDF)

Tumor infiltrating lymphocytes in patients receiving trastuzumab/pertuzumab-based chemotherapy: A TRYPHAENA substudy

European journal of cancer (1990), 2018-04, Vol.92, p.S15

2018

Volltextzugriff (PDF)

22 - Tumor infiltrating lymphocytes in patients receiving trastuzumab/pertuzumab-based chemotherapy: A TRYPHAENA substudy

European journal of cancer (1990), 2018-04, Vol.92, p.S15-S15

2018

Volltextzugriff (PDF)

Abstract OT3-05-02: ALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early triple negative breast cancer

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.OT3-05-02-OT3-05-02

2019

Volltextzugriff (PDF)

14P Comparison of single-cell ERBB2 mRNA expression levels with HER2 status by immunohistochemistry reveals heterogeneity of the HER2-low status

ESMO open, 2023-05, Vol.8 (1), p.101238, Article 101238

2023

Volltextzugriff (PDF)

Abstract P4-21-09: Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2 positive early breast cancer (BIG 1-06)

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P4-P4-21-09

2017

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer

Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer

Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4

The AURORA initiative for metastatic breast cancer

Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers

Corrigendum to “Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer”: [Annals of Oncology 33 (2022) 769–785]

SYNERGY: Phase I and randomized phase II trial to investigate the addition of the anti-CD73 antibody oleclumab to durvalumab, paclitaxel and carboplatin for previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)

Neoadjuvant biomarker research study of palbociclib combined with endocrine therapy in estrogen receptor positive/HER2 negative breast cancer: The phase II NeoRHEA trial

Perianal Mucinous Adenocarcinoma Arising from a Chronic Fistula-In-Ano

1811 Expression levels of ERBB2, ESR1, immune and proliferation signatures measured by RNASeq predict response to anti-HER2 treatment in the neoALTTO trial

2251P The genomic landscape of radiotherapy-induced breast angiosarcoma: An alleanza contro il cancro (ACC) initiative for an unmet need in rare tumors

Mdm4 and Mdm2 Cooperate to Inhibit p53 Activity in Proliferating and Quiescent Cells in vivo

139MO Identification of biologically-driven HER2-positive breast cancer subgroups associated with prognosis after adjuvant trastuzumab in the ALTTO trial

67P Digital analysis of distant and cancer-associated adipocytes in breast cancer

ALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early stage triple negative breast cancer

289TiP - ALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early stage triple negative breast cancer

91P The lack of documentation of patient’s body mass index (BMI) in recent clinical trials

Abstract P1-05-02: Genomic, transcriptomic and immune features of breast cancer according to the patient's body mass index at diagnosis

Abstract P2-05-04: Deregulation of A-to-I RNA editing is associated with poor prognosis in HER2+ breast cancers in the neoALTTO trial

Tumor infiltrating lymphocytes in patients receiving trastuzumab/pertuzumab-based chemotherapy: A TRYPHAENA substudy

22 - Tumor infiltrating lymphocytes in patients receiving trastuzumab/pertuzumab-based chemotherapy: A TRYPHAENA substudy

Abstract OT3-05-02: ALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early triple negative breast cancer

Histopathological growth patterns and tumor-infiltrating lymphocytes in breast cancer liver metastases

14P Comparison of single-cell ERBB2 mRNA expression levels with HER2 status by immunohistochemistry reveals heterogeneity of the HER2-low status

Abstract P4-21-09: Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2 positive early breast cancer (BIG 1-06)

Suchergebnisse filtern